Nomura
http://www.nomura.com/Nomura (NYSE: NMR) is a global investment banking and securities firm. The firm’s operations include Domestic Retail, Global Markets, Global Investment Banking, Global Merchant Banking, and Asset Management. Nomura is headquartered in Tokyo, Japan.
Nomura is represented in the Americas by Nomura Holding America (NHA). NHA’s major divisions are Fixed Income, Investment Banking, Equities and Asset Management.
View Older Stories View More Recent Stories
-
Post Holdings Announces Proposed Common Stock Offering
-
Michaels Cos. (MIK) 18.8M Secondary Offering Prices at $23.52/Share
-
Notable Analyst Rating Changes 1/22: (CHUY) (ALU) (AMCX) Upgraded; (EMR) (AZPN) (ADVS) Downgraded
-
Raymond James (RJF) Q1 Results 'Good Enough', Nomura Says
-
Discover Financial (DFS) PT Cut to $68 at Nomura Post Q4; 'Buy' Maintained
-
Xilinx (XLNX) PT, Estimates Cut at Nomura Posts Q3
-
Nomura Securities Upgrades AMC Networks (AMCX) to Buy
-
Notice Regarding UBIC's Additional Acquisition of Shares of UBIC Risk Consulting, Inc. (100% Ownership) and Absorption-Type Merger (by Way of Simplified Merger)
-
Wall Street Sings Netflix (NFLX) Praises Following Strong Fourth-Quarter Earnings
-
Nomura Securities Upgrades Netflix (NFLX) to Buy Post Q4; 5 Reasons Cited
-
Nomura Securities Downgrades Las Vegas Sands (LVS), Wynn Resorts (WYNN) to Neutral; MGM (MGM) Maintained at Buy
-
Nomura Securities Downgrades SanDisk (SNDK) to Reduce; Shares headed to Mid-$60s
-
Form 6-K NOMURA HOLDINGS INC For: Jan 16
-
Notable 52-Week Highs and Lows 1/15: (KRFT) (MO) (XON) High; (KBH) (EHTH) (PODD) Low
-
Reynolds American (RAI) PT Raised to $79 at Nomura Securities on Increased Deal Approval Probability
-
UPDATE: Nomura Securities Upgrades Altria (MO) to Buy
-
BioMarin (BMRN) PT Lifted to $123 at Nomura Securities Following Meeting with Management
-
Nomura Weighs In on Gilead Sciences (GILD) Following Meeting with Management
-
Yahoo! (YHOO) PT Raised to $59 at Nomura Securities Ahead of Expected Corporate Action
-
Bank of America (BAC) Revenue Miss Overshadows Lower-Quality Beat, Nomura Securities Says
-
Nomura Provides Initial Thoughts on SNB Move; May Signal ECB QE is Imminent and Big
-
Notable Analyst Rating Changes 1/14: (BEBE) (DTSI) (DRE) Upgraded; (TRUE) (IRBT) (ATHM) Downgraded
-
Nomura Securities Starts Workday (WDAY) at Neutral
-
Nomura Securities Upgrades CNOOC Ltd. (CEO) to Neutral
-
Form 6-K NOMURA HOLDINGS INC For: Jan 14
-
Notable Analyst Rating Changes 1/12: (FTR) (CHK) (AA) Upgraded; (ADT) (WNR) (DHI) Downgraded
-
Nomura Securities Starts Johnson Controls (JCI) at Neutral
-
Alcoa (AA) Upgraded to Buy at Nomura Ahead of Tonight's Earnings Report
-
Bed Bath & Beyond (BBBY) Q3 Results In-Line, PT Raised to $76 at Nomura
-
Nomura Securities Upgrades XL Group plc (XL) to Buy
-
Nomura Securities Starts ULTA Salon (ULTA) at Neutral
-
Nomura Securities Starts Sally Beauty Holdings (SBH) at Neutral
-
Nomura Securities Starts Mead Johnson Nutrition (MJN) at Buy; Better U.S. Birth Rates, Consistency in China
-
Nomura Securities Upgrades Anheuser-Busch InBev (BUD) to Buy
-
Nomura Securities Downgrades Diageo plc (DEO) to Neutral
-
Nomura Securities Upgrades Molson Coors (TAP) to Buy; Lower Gas Prices Means More Beer Drinking
-
Nomura Discuses Implication for Google (GOOG) on Potential Loss as Apple (AAPL) Default Search Engine
-
Synageva BioPharma (GEVA) Prices Larger 3M Common Offering at $94.19/Share
-
Synageva (GEVA) PT Raised to $124 at Nomura
-
Receptos (RCPT) PT Raised to $173 at Nomura
-
Gilead Sciences (GILD) PT Trimmed to $146 at Nomura; 'Buy' Maintained
-
Amgen (AMGN) PT Raised to $200 at Nomura
-
Neurocrine Bio. (NBIX) Named Top 2015 Small-Cap Biotech Pick at Nomura; PT Raised to $34
-
BioMarin (BMRN) Named Top 2015 Mid-Cap Biotech Pick at Nomura
-
Celgene (CELG) Named Top Large Cap Biotech Pick for 2015 at Nomura; PT Raised to $150
-
Pre-Open Stock Movers 1/5: (CNAT) (STXS) (URZ) (CEMP) Higher; (BCLI) (OAS) (SNY) Lower (more...)
-
Nomura Securities Downgrades Pharmacyclics (PCYC) to Neutral
-
Nomura Securities Downgrades Alexion Pharmaceuticals (ALXN) to Neutral
-
Nomura Securities Downgrades Biogen (BIIB) to Neutral
-
Form 6-K NOMURA HOLDINGS INC For: Jan 05

